Hormone · FDA Approved
GHRH (Sermorelin 1-44)
FDA-approved
01 · Overview
Growth hormone releasing hormone (GHRH) is a 44-amino acid hypothalamic peptide that stimulates growth hormone secretion from the anterior pituitary by binding to GHRH receptors. Sermorelin is a synthetic analogue corresponding to the first 29 amino acids of GHRH, known as GHRH(1-29), which was the form developed clinically (PMID 8772599).
Sermorelin was marketed in the United States as Geref for diagnostic testing of growth hormone secretion and later for treatment of growth hormone deficiency in children, but the product has since been discontinued.
02 · Research summary & key findings
The FDA first approved sermorelin acetate (Geref) in 1990, with a second application approved in 1997; both are now listed as discontinued. In a one-year multicenter study of 110 previously untreated prepubertal children with growth hormone deficiency, once-daily subcutaneous GHRH(1-29) increased mean height velocity from 4.1 to 7.2 cm per year at 12 months without excessive bone age advancement and was well tolerated (PMID 8772599). Full-length GHRH(1-44) itself has not been approved by the FDA as a drug product.
03 · Regulatory status
GHRH (Sermorelin 1-44) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
GHRH (Sermorelin 1-44) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for hormone optimization?
GHRH (Sermorelin 1-44) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group J Clin Endocrinol Metab, 1996. PMID 8772599
Primary literature
- PubMed: "GHRH"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "GHRH"
Registered interventional and observational studies, including status and phase.
- PubChem: "GHRH"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.